within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC13_Ixekizumab;

model Ixekizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.472222222222223e-09,
    adminDuration = 600,
    adminMass = 160 / 1000000,
    adminCount = 1,
    Vd = 0.00711,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.004690000000000001,
    k12 = 3.833333333333334e-09,
    k21 = 3.833333333333334e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ixekizumab</td></tr><tr><td>ATC code:</td><td>L04AC13</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>160</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>7.11</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.0161</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a pro-inflammatory cytokine. It is used for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Ixekizumab is approved by regulatory agencies, including the FDA and EMA, for these indications.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis. Parameters were evaluated following subcutaneous administration in both males and females, aged 18 to 75 years.</p><h4>References</h4><ol><li><p>Zheng, M, et al., &amp; Zheng, J (2023). Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study. <i>Advances in therapy</i> 40(9) 3804–3816. DOI:<a href=\"https://doi.org/10.1007/s12325-023-02575-1\">10.1007/s12325-023-02575-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37356077/\">https://pubmed.ncbi.nlm.nih.gov/37356077</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AC13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ixekizumab;
